In the complex and often devastating progression of pancreatic cancer, the moment of metastasis—when malignant cells break away from the primary tumor to colonize distant organs—marks a critical and frequently terminal turning point. For decades, oncologists and molecular biologists have struggled to understand why certain cancer cells migrate to specific organs and how they manage to survive in environments that are fundamentally different from the pancreas. Now, a team of scientists at the University of California, San Francisco (UCSF) has identified a primary molecular driver behind this process, revealing that a single protein acts as a metabolic switch, allowing pancreatic cancer cells to adapt to the wildly varying conditions of the liver and the lungs.
The study, published May 21 in the journal Nature, centers on a protein known as PCSK9. While PCSK9 is well-known in the field of cardiology for its role in regulating blood cholesterol levels, the UCSF team discovered that pancreatic cancer cells hijack this protein to navigate the metabolic demands of metastasis. By manipulating PCSK9 levels, the researchers found they could essentially dictate where a tumor would spread, providing a potential new roadmap for therapeutic intervention in a disease that has long been considered one of the most difficult to treat.
Pancreatic cancer is notoriously aggressive, often remaining asymptomatic until it has already begun to infiltrate other parts of the body. By the time a patient presents with symptoms such as jaundice, weight loss, or abdominal pain, the cancer has frequently already established colonies in the liver or the lungs. This late-stage diagnosis is a primary reason why the five-year survival rate remains stubbornly low compared to other forms of the disease. The UCSF findings offer a glimmer of hope by shifting the focus from the tumor’s genetic mutations to its metabolic flexibility, suggesting that the "seeds" of cancer must carefully choose their "soil" based on the nutrients available.
To understand this phenomenon, the research team looked at the starkly different biological landscapes cancer cells encounter when they leave the pancreas. They likened the transition to animals moving between an ocean and a desert; an organism adapted for the high-moisture, nutrient-dense environment of the sea would quickly perish in the arid heat of a wasteland unless it possessed a mechanism to change its fundamental physiology. In the human body, the liver and the lungs represent these two extremes. The liver is a metabolic powerhouse, rich in nutrients and specifically abundant in cholesterol. The lungs, by contrast, are high-oxygen environments that present significant oxidative stress to invading cells, with far less readily available cholesterol for a growing tumor to scavenge.
The investigation began with an extensive analysis of data from MetMap, a comprehensive project hosted by the Broad Institute. MetMap is an independent research initiative designed to map the metastatic potential of hundreds of human cancer cell lines. By diving into this data, the UCSF researchers identified specific pancreatic cancer cell lines that demonstrated a clear preference for either the liver or the lungs. With these distinct groups identified, the team performed a deep genomic and proteomic comparison to see what, if anything, differentiated a "liver-bound" cell from a "lung-bound" cell.
The analysis consistently pointed toward PCSK9. The protein appeared to function as a regulatory valve for how the cancer cells obtained cholesterol, a vital building block for cell membranes and a necessary resource for rapid cell division. The researchers found that when PCSK9 levels were low, the cancer cells were primed to thrive in the liver. In this state, the cells did not need to expend energy producing their own cholesterol; instead, they became highly efficient at absorbing the cholesterol that is naturally plentiful in the liver’s environment.
Conversely, when the researchers examined cells that had successfully colonized the lungs, they found high levels of PCSK9. In the cholesterol-poor environment of the lungs, cancer cells cannot rely on external sources to fuel their growth. High levels of PCSK9 signaled the cells to undergo a dramatic metabolic shift, triggering them to synthesize their own cholesterol internally. Perhaps even more importantly, the researchers discovered that this high-PCSK9 state also prompted the production of specific antioxidant molecules. These molecules act as a shield, protecting the cancer cells from the damaging effects of reactive oxygen species, which are prevalent in the oxygen-rich tissues of the lung.
To test whether PCSK9 was merely a marker of where the cancer went or the actual cause of its destination, the UCSF team conducted a series of "forced expression" experiments. They took pancreatic cancer cells that were genetically predisposed to migrate to the liver—cells with naturally low PCSK9—and artificially boosted their PCSK9 production. The results were striking: the cells that would have normally settled in the liver instead made a metabolic detour, successfully colonizing the lungs. This demonstrated that PCSK9 is a functional switch that determines the metastatic fate of the cell.
"Cancers persist by adapting to live in new tissues and organs, and we found that pancreatic tumors use PCSK9 to adapt as they spread," said Rushika Perera, PhD, the Deborah Cowan Endowed Associate Professor of Anatomy at UCSF and the senior author of the paper. Dr. Perera emphasized that this discovery provides a new perspective on the resilience of metastatic tumors. By understanding the metabolic requirements of a cell in a specific organ, scientists can begin to look for ways to "starve" the cancer or prevent it from adapting to its new home. "It opens the door to fighting metastatic cancer growth by manipulating how cells acquire their cholesterol," she added.
The implications for treatment are significant. Pancreatic cancer has earned a reputation for being "notoriously resistant" to conventional chemotherapy and targeted treatments. Much of this resistance stems from the tumor’s ability to create a protective microenvironment and its capacity to pivot its internal chemistry when under attack. If clinicians can target the PCSK9 pathway, they might be able to prevent the cancer from establishing itself in the lungs or make liver metastases more vulnerable to existing drugs.
Interestingly, because PCSK9 inhibitors are already a class of drugs used to treat high cholesterol in cardiovascular patients, there is a wealth of existing knowledge regarding how to safely inhibit this protein in humans. While the application in oncology would require extensive clinical trials and a different approach to dosing and delivery, the fact that the protein is already a known therapeutic target could accelerate the development of new treatments.
The study also highlights the growing importance of metabolic research in oncology. For many years, the primary focus of cancer research was on DNA mutations—the "broken blueprints" that cause cells to grow out of control. However, the UCSF study suggests that the "fuel" the cells use is just as important as the genetic mutations that drive them. By focusing on the metabolic vulnerabilities of metastatic cells, researchers are finding new ways to intervene in the disease process that were previously overlooked.
The collaborative nature of the study was also a key factor in its success. The work was supported by a diverse array of major scientific organizations, including the National Institutes of Health (NIH), the National Science Foundation (NSF), and the American Association for Cancer Research (AACR). This multi-agency backing underscores the perceived importance of the findings within the broader scientific community and the urgent need for new strategies to combat pancreatic adenocarcinoma.
As the research moves forward, the UCSF team and their collaborators will likely look into whether this PCSK9 mechanism is unique to pancreatic cancer or if it is a strategy employed by other types of metastatic cancers, such as those of the breast or colon. Furthermore, the discovery of the antioxidant protection provided by high PCSK9 levels in the lungs suggests that combining PCSK9 inhibitors with treatments that increase oxidative stress could be a potent "one-two punch" against lung metastases.
For now, the study stands as a major step forward in deconstructing the survival tactics of one of the world’s most lethal cancers. By identifying the molecular machinery that allows pancreatic cancer to bridge the gap between the "ocean" of the liver and the "desert" of the lungs, the UCSF team has provided a new target in the ongoing effort to turn a late-stage diagnosis from a death sentence into a manageable condition. The discovery that PCSK9 dictates the path of spread provides not just a clearer understanding of the biology of metastasis, but a tangible point of entry for the next generation of cancer therapies.
